Alfuzosin Hydrochloride NDC 51655-087

NDC codes

FDA NDC Directory

Product NDC (as listed)51655-087Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51655-0087Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51655-087-52	51655008752	30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (51655-087-52)Marketed from Oct 4, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alfuzosin Hydrochloride
Generic name (nonproprietary): alfuzosin hydrochloride
Active ingredients: Alfuzosin hydrochloride — 10 mg/1
Dosage form: Tablet, Film coated, Extended release
Route: Oral
Labeler: Northwind Health Company, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 079060
Marketing start: Oct 4, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 51655-087_46ddcd42-e20f-656c-e063-6294a90a7e5fSPL ID 46ddcd42-e20f-656c-e063-6294a90a7e5fSPL set ID f2a530bd-6a86-251d-e053-2995a90adac4RxCUI 861132UNII 75046A1XTN
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451655008752 followed by a unit qualifier and the quantity

Package 51655-0087-52. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 26, 2025.

Indications (excerpt from the label)

Alfuzosin hydrochloride extended-release tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Alfuzosin hydrochloride extended-release tablets are an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. (1) Important Limitations of Use: Alfuzosin hydrochloride extended-release tablets are not indicated for treatment of hypertension. (1.1) Alfuzosin hydrochloride extended-release tablets are not indicated for use in the pediatric population. (1.1 , 8.4 , 12.3 ) 1.1 Important Limitations of Use Alfuzosin hydrochloride extended-release tablets are not indicated for the treatment of hypertension.…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 079060

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 079060
Product	Strength	Form · route	Labeler	Product NDC
Alfuzosin Hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Film coated, Extended releaseOral	Bryant Ranch Prepack	71335-2578
Alfuzosin Hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Film coated, Extended releaseOral	Aurobindo Pharma Limited	65862-249
Alfuzosin Hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Film coated, Extended releaseOral	Aurobindo Pharma Limited	84386-153
Alfuzosin Hydrochloride	Alfuzosin hydrochloride 10 mg/1	Tablet, Film coated, Extended releaseOral	Rising Pharma Holdings, Inc.	57237-114